X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (37) 37
gastroenterology & hepatology (36) 36
humans (36) 36
male (32) 32
adult (31) 31
female (31) 31
gastroenterology and hepatology (27) 27
infliximab (25) 25
middle aged (24) 24
crohn disease - drug therapy (21) 21
crohn's disease (20) 20
crohns-disease (16) 16
antibodies, monoclonal - therapeutic use (15) 15
inflammatory bowel disease (14) 14
treatment outcome (14) 14
abridged index medicus (12) 12
ulcerative colitis (12) 12
aged (11) 11
therapy (11) 11
adolescent (10) 10
colitis, ulcerative - drug therapy (10) 10
gastrointestinal agents - therapeutic use (10) 10
rheumatoid-arthritis (10) 10
ulcerative-colitis (10) 10
young adult (10) 10
inflammatory-bowel-disease (9) 9
prospective studies (9) 9
antibodies, monoclonal - administration & dosage (8) 8
antibodies, monoclonal - adverse effects (8) 8
drug administration schedule (8) 8
c-reactive protein (7) 7
case-control studies (7) 7
cohort studies (7) 7
crohn disease - immunology (7) 7
crohn disease - pathology (7) 7
inflammatory bowel diseases (7) 7
antibodies, monoclonal - immunology (6) 6
follow-up studies (6) 6
inflammatory bowel diseases - drug therapy (6) 6
tumor necrosis factor (6) 6
tumor necrosis factor-alpha - antagonists & inhibitors (6) 6
anti-inflammatory agents - therapeutic use (5) 5
belgium (5) 5
drug therapy (5) 5
gastrointestinal agents - administration & dosage (5) 5
induction (5) 5
medical research (5) 5
tumor necrosis factor-alpha - immunology (5) 5
analysis (4) 4
anti-inflammatory agents - administration & dosage (4) 4
anti-inflammatory agents - adverse effects (4) 4
anti-tnf therapy (4) 4
antibodies (4) 4
antibodies, monoclonal - pharmacokinetics (4) 4
care and treatment (4) 4
colitis, ulcerative - diagnosis (4) 4
colitis, ulcerative - pathology (4) 4
crohn disease - diagnosis (4) 4
drug therapy, combination (4) 4
gastrointestinal agents - adverse effects (4) 4
gastrointestinal agents - immunology (4) 4
immunosuppressive agents - administration & dosage (4) 4
immunosuppressive agents - therapeutic use (4) 4
intestinal mucosa - pathology (4) 4
maintenance (4) 4
maintenance therapy (4) 4
medicine, experimental (4) 4
monoclonal antibodies (4) 4
necrosis-factor-alpha (4) 4
prognosis (4) 4
remission (4) 4
safety (4) 4
time factors (4) 4
adalimumab (3) 3
antibodies, monoclonal - blood (3) 3
antibodies, monoclonal, humanized (3) 3
antibodies, monoclonal, humanized - therapeutic use (3) 3
azathioprine - administration & dosage (3) 3
c-reactive protein - analysis (3) 3
clinical trials (3) 3
colitis (3) 3
colonoscopy (3) 3
crohn disease - surgery (3) 3
crohns disease (3) 3
efficacy (3) 3
factor-alpha (3) 3
gastrointestinal agents - blood (3) 3
gastrointestinal agents - pharmacology (3) 3
ibd (3) 3
immunosuppressive agents - adverse effects (3) 3
infusions, intravenous (3) 3
injections, intravenous (3) 3
intestinal mucosa - drug effects (3) 3
intestine (3) 3
medical therapy (3) 3
medicine, general & internal (3) 3
methotrexate (3) 3
predictors (3) 3
prevention (3) 3
randomized-trial (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Gut, ISSN 0017-5749, 2007, Volume 56, Issue 9, pp. 1226 - 1231
Journal Article
Journal Article
Gut, ISSN 0017-5749, 02/2012, Volume 61, Issue 2, pp. 229 - 234
Journal Article
Journal Article
Gastroenterology, ISSN 0016-5085, 2009, Volume 137, Issue 5, pp. 1628 - 1640
Journal Article
Journal Article
Gastroenterology, ISSN 0016-5085, 2008, Volume 134, Issue 7, pp. 1861 - 1868
Background & Aims: The benefit to risk ratio of concomitant immunosuppressives with scheduled infliximab (IFX) maintenance therapy for Crohn's disease is an... 
Gastroenterology and Hepatology | RHEUMATOID-ARTHRITIS | ANTIBODIES | MULTICENTER | INFLAMMATORY-BOWEL-DISEASE | THERAPY | SERUM INFLIXIMAB | LYMPHOMA | RISK | INDUCTION | GASTROENTEROLOGY & HEPATOLOGY | SHORT-TERM | Azathioprine - administration & dosage | Prospective Studies | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Gastrointestinal Agents - administration & dosage | Crohn Disease - metabolism | Male | Intestinal Mucosa - drug effects | Anti-Inflammatory Agents - adverse effects | C-Reactive Protein - metabolism | Infliximab | Adult | Anti-Inflammatory Agents - administration & dosage | Anti-Inflammatory Agents - pharmacokinetics | Female | Drug Therapy, Combination | France | Gastrointestinal Agents - pharmacokinetics | Immunosuppressive Agents - administration & dosage | Drug Administration Schedule | Mercaptopurine - administration & dosage | Antibodies, Monoclonal - pharmacokinetics | Treatment Outcome | Belgium | Antibodies, Monoclonal - administration & dosage | Crohn Disease - pathology | Crohn Disease - drug therapy | Methotrexate - administration & dosage | Gastrointestinal Agents - adverse effects | Infusions, Intravenous | Intestinal Mucosa - pathology | Clinical trials | Crohn's disease | C-reactive protein | Tumor necrosis factor | Immunotherapy | Index Medicus | Abridged Index Medicus | Life Sciences | Human health and pathology | Hépatology and Gastroenterology
Journal Article
Inflammatory Bowel Diseases, ISSN 1078-0998, 09/2011, Volume 17, Issue 9, pp. 1846 - 1854
Background: Infliximab (IFX) and adalimumab (ADA) are attractive treatment options in patients with inflammatory bowel disease (IBD) also during pregnancy but... 
direct exposure to anti‐TNF | intentional treatment | pregnancy outcome | anti‐TNF treatment | inflammatory bowel disease | direct exposure to anti-TNF | anti-TNF treatment |